Undisclosed DDRi-ADC / Artios Pharma - LARVOL DELTA

Artios Announces Oversubscribed $115 Million Series D Financing to Accelerate Clinical Programs in Indications of High Unmet Need (Artios Press Release) - "The Series D proceeds will expand the clinical evaluation of Artios’ lead program, alnodesertib, to enroll additional ATM-negative patients in each of second-line pancreatic cancer and third-line colorectal cancer...The proceeds from the financing will also be used to initiate a Phase 2 randomized clinical trial for Artios’ second potential first-in-class candidate, ART6043, in patients with BRCA-mutant HER2-negative breast cancer who are eligible to receive a PARP inhibitor...The company is also advancing a first-in-class and highly differentiated DDR inhibitor-Antibody Drug Conjugate (DDRi-ADC) program and expects to name a lead candidate in Q1 2026."

Financing • New P2 trial • Pipeline update • Colorectal Cancer • HER2 Negative Breast Cancer • Pancreatic Cancer